1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. News
  7. Summary
    GSK   GB00BN7SWP63


Real-time Estimate Cboe Europe  -  10:23 2022-08-12 am EDT
1443.30 GBX   +3.09%
10:00aBiotech stocks pin bounce back hopes on M&A boost
08:53aFDA and EMA have concluded there is no evidence of a causal association between ranitidine therapy and the development of cancer
06:25aSTATEMENT : Zantac (ranitidine) litigation - Form 6-K
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community

06/29/2022 | 08:08am EDT

Inaugural grant awarded to the HealthTree Foundation, a pioneering non-profit organization whose proposal will address disparities in care in multiple myeloma

GSK plc today announced the first recipient of the Target the Future Think Tank Challenge £70,000 (equivalent to approximately $100,000) grant to the HealthTree Foundation, a non-profit organization helping patients learn more about their health and become their own best advocates. Their proposal, the “HealthTree Equity and Diversity for Multiple Myeloma Program,” will improve access, education and support for underserved communities and minority patients.

Tania Small, Vice President, Global Head of Oncology Medical Affairs and Head of R&D Diversity, Equity and Inclusion at GSK, said: “The response to this challenge showcased an abundance of innovation, creativity and ingenuity, which we need to address patients’ unmet needs. We see great potential in the HealthTree Foundation’s proposal, which goes beyond the science to improve access, equitable care and quality of life for the multiple myeloma community.”

GSK’s grant will help support the HealthTree Foundation as it develops digital delivery tools to distribute information on treatments and trials, facilitate digital communities and expand outreach efforts to support, educate and provide more equitable care to multiple myeloma patients.

Jenny Ahlstrom, Founder and CEO of the HealthTree Foundation, said: “I am alive today because I had the right information and treatments, and we must extend that access to communities of color. GSK saw problems and created a program to target a better future. Because of GSK’s support, we can implement a strategy to help our community by providing necessary tools to broaden awareness. We’re ready to make a difference in this underserved population suffering from multiple myeloma.”

Specifically, the Target the Future grant from GSK will aid in the expansion of two of the following initiatives at the HealthTree Foundation:

  • “Black Myeloma Health”: Outreach from the HealthTree Foundation will expand to spotlight Black patients with multiple myeloma and their experiences through video journaling and distribution of new educational brochures with information about relevant treatments and resources. It will also create distinct communities online for Black patients and caregivers to come together and support each other.
  • “HealthTree for Mieloma Multiple”: The organization’s efforts to support multiple myeloma patients will increase through deployment of Spanish-speaking patient navigators who will help people get answers along their treatment journey in their native language. It will also create referral forms in Spanish at clinics and translate existing HealthTree Foundation materials so more patients can access and understand information relevant to their care.

About the Target the Future Think Tank Challenge
Target the Future is an international, multi-year initiative dedicated to advancing innovation and addressing key needs in the multiple myeloma community. The Think Tank Challenge issued a clarion call for innovative ideas to support patients. GSK assembled a multidisciplinary advisory group of people personally and professionally connected to the multiple myeloma community and evaluated the top 20 submissions from around the world.

Entries came in from patients, caregivers, healthcare professionals, developers, researchers, advocates and non-profits. Following finalist presentations, the panel evaluated ideas on novelty, feasibility to execute and ability to address unmet needs. The panel unanimously voted in favor of the inaugural winner. GSK will share detailed updates as the HealthTree Foundation’s idea comes to life and report on results of this effort within the community.

The Think Tank Challenge will issue the next call for submissions in the second half of 2022. To learn more about GSK’s Target the Future program and ways GSK is collaborating with the community to get ahead of this disease together, please visit https://targetthefuturemm.com.

GSK in Oncology
GSK is focused on maximizing patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, tumor cell targeting therapies and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody-drug conjugates and cell therapy, either alone or in combination.

About GSK
GSK is a science-led global healthcare company. For further information please visit https://us.gsk.com/en-us/about-us.

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK’s Q1 Results for 2022 and any impacts of the COVID-19 pandemic.

Registered in England & Wales:
No. 3888792

Registered Office:
980 Great West Road
Brentford, Middlesex

© Business Wire 2022
All news about GSK PLC
10:00aBiotech stocks pin bounce back hopes on M&A boost
08:53aFDA and EMA have concluded there is no evidence of a causal association between ranitid..
06:25aSTATEMENT : Zantac (ranitidine) litigation - Form 6-K
05:42aEUROPEAN MIDDAY BRIEFING : Shares Edge Higher as Inflation Fears Ease
05:11aNORTH AMERICAN MORNING BRIEFING : Stock Futures Rise as Debate Over Inflation's Path Conti..
04:58aFTSE 100 rises after better-than-feared GDP reading
04:47aEuropean shares rise as healthcare rebounds, travel stocks gain
04:24aGSK, Sanofi and Haleon shares stabilise after Zantac litigation slump
03:30aLONDON STOCK EXCHANGE : FTSE 100 climbs on smaller-than-expected GDP contraction, GSK rebo..
More news
Analyst Recommendations on GSK PLC
More recommendations
Sales 2022 29 644 M 36 203 M 36 203 M
Net income 2022 4 364 M 5 329 M 5 329 M
Net Debt 2022 15 314 M 18 703 M 18 703 M
P/E ratio 2022 12,9x
Yield 2022 4,26%
Capitalization 56 676 M 69 216 M 69 216 M
EV / Sales 2022 2,43x
EV / Sales 2023 2,25x
Nbr of Employees 90 096
Free-Float 93,6%
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 1 400,00 GBX
Average target price 2 038,46 GBX
Spread / Average Target 45,6%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Jon Ellis VP & Head-Technology Business Development
Tony Wood Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC-14.82%69 216
JOHNSON & JOHNSON-2.30%439 441
ROCHE HOLDING AG-18.19%272 759
PFIZER, INC.-18.22%271 020
ABBVIE INC.4.93%251 211